Tamoxifen
Selective estrogen receptor modulator (SERM). Adjuvant and metastatic treatment of hormone receptor-positive breast cancer (Nolvadex).
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.
DETAILED OVERVIEW
What is Tamoxifen?
Tamoxifen is the first clinically major SERM, developed by AstraZeneca (Nolvadex, FDA 1977). In ER+ breast cancer adjuvant treatment with 5-10 year protocol, reduces relapse risk by 50% (EBCTCG 2011 Lancet PMID 21684593). In premenopausal women, aromatase inhibitors (anastrozole, letrozole) ineffective, so tamoxifen is first-line SERM. Side effect profile: thromboembolism (DVT, PE 2-3x rise), endometrial cancer risk (~2x), menopausal-like symptoms (hot flashes). ER+ DCIS prevention and high-risk primary prevention FDA-approved (NSABP-P1 trial).
ATC code
L02BA01
Prescription
Prescription only (Rx), oncologist-supervised
Mechanism
Selective estrogen receptor modulator (SERM), breast antagonist
Half-life
5-7 days (parent), N-desmethyl metabolite ~14 days
Onset
Months to years (adjuvant clinical response)
Nolvadex (Tamoxifen) and Raloxifene are anecdotally the two most reliable compounds for gyno prevention, because tamoxifen directly blocks estrogen at the receptor level selectively in breast tissue – a highly targeted mechanism. Unlike Arimidex, it is not an aromatase inhibitor, so the benefits are receptor-targeted rather than system-wide. It is commonly used in PCT protocols because it stimulates LH/FSH more directly, which can be useful for HPTA recovery. Reported side effects include mild mood swings, rare vision disturbances, and long-term blood-clot risk – though most clotting case reports come from postmenopausal women using it for breast cancer prevention, so applicability to AAS users is less clear. Overall, community accounts regard Nolvadex as a solid tool for blocking estrogen in breast tissue and a strong gyno-prevention option. Administered orally, with dosing typically structured in multi-week cycles, especially during PCT.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Early Breast Cancer Trialists' Collaborative Group. . Relevance of breast cancer hormone receptors and outcomes of 5 years of tamoxifen (EBCTCG). Lancet. 2011;378(9793):771-84..
Fisher B, Costantino JP, Wickerham DL et al. . Tamoxifen for prevention of breast cancer (NSABP-P1). J Natl Cancer Inst. 1998;90(18):1371-88..
Goetz MP, Sangkuhl K, Guchelaar HJ et al. . CYP2D6 genotype and tamoxifen efficacy. Clin Pharmacol Ther. 2018;103(5):770-777..
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism) and stroke, 2-3x increased risk, a serious boxed-style warning, higher around immobilization or surgery. Seek emergency care for one-sided leg swelling, sudden breathlessness or chest pain.
- Endometrial changes: hyperplasia, polyps, endometrial carcinoma and rarely uterine sarcoma, roughly 2x cancer risk, a serious warning. Any abnormal vaginal bleeding must be investigated.
- Menopause-like symptoms: hot flushes, sweating, mood swings, vaginal discharge or dryness, menstrual irregularities, reduced libido. Among the most common, affecting 40-60% of patients.
- Ocular effects: cataract, retinopathy and rarely corneal deposits, visual disturbance. New or worsening vision problems warrant an ophthalmology review.
- Hepatic effects: hepatic steatosis (fatty liver), raised liver enzymes, rarely serious hepatotoxicity (cholestasis, hepatitis). Periodic liver function monitoring is advised.
- Tumour flare at treatment start: transient bone or tumour pain, hypercalcemia, due to bone metastases. Often a sign of efficacy but requires monitoring.
- Reduced efficacy when combined with strong CYP2D6 inhibitors: fluoxetine, paroxetine and bupropion lower active endoxifen levels and thus the antitumour effect. These should be avoided where possible.
- Other common effects: nausea, abdominal discomfort, fluid retention and edema, fatigue, headache, rash, and reduced blood counts (leukopenia, thrombocytopenia).
Contraindications · 3
- Pregnancy (category D, fetal damage)
- Active thromboembolism (DVT, PE) or within-1-year history
- Untreated endometrial hyperplasia
Studies
Related research and clinical findings
Relevance of breast cancer hormone receptors and outcomes of 5 years of tamoxifen (EBCTCG)
Early Breast Cancer Trialists' Collaborative Group.
Tamoxifen for prevention of breast cancer (NSABP-P1)
Fisher B, Costantino JP, Wickerham DL et al.
CYP2D6 genotype and tamoxifen efficacy
Goetz MP, Sangkuhl K, Guchelaar HJ et al.
Telegram
Have a question about Tamoxifen?
Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.